Entecavir Tablets, offered by Kureasia Pharma, are a highly effective antiviral medication used in the management and treatment of chronic hepatitis B virus (HBV) infection. Formulated in precise strengths of 0.5 mg and 1 mg, these tablets are designed to inhibit HBV replication, reduce viral load, and prevent the progression of liver disease, including cirrhosis and hepatocellular carcinoma. Manufactured under stringent quality standards, Entecavir Tablets from Kureasia Pharma ensure superior efficacy, stability, and patient safety, making them a reliable choice for healthcare professionals worldwide.
Mechanism of Action:
Entecavir is a potent and selective guanosine nucleoside analogue that inhibits the HBV DNA polymerase enzyme. It blocks all three functional activities of this enzyme—base priming, reverse transcription of the negative strand, and synthesis of the positive strand of HBV DNA. By interfering with viral replication, Entecavir effectively reduces HBV DNA levels in the bloodstream and promotes improvement in liver function over time.
Pharmacological Benefits:
Demonstrates strong antiviral potency and rapid viral suppression.
Effective against both wild-type and lamivudine-resistant strains of HBV.
Low incidence of viral resistance with long-term therapy.
Improves histological and biochemical markers of liver health.
Well tolerated with a favorable safety and side effect profile.
Indications:
Entecavir Tablets are indicated for:
The treatment of chronic hepatitis B infection in adults and adolescents with evidence of active viral replication and either persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Patients who are nucleoside-naïve or who have developed resistance to other HBV therapies such as lamivudine.
Dosage and Administration:
The recommended dose for nucleoside-naïve adults is 0.5 mg once daily.
For patients with lamivudine-resistant HBV, the dosage is 1 mg once daily.
Entecavir should be taken on an empty stomach (at least 2 hours before or after a meal) for optimal absorption.
Dosage adjustments may be required for patients with renal impairment.
Safety and Precautions:
Regular monitoring of hepatic function, HBV DNA levels, and renal parameters is advised during therapy.
Discontinuation of treatment may result in severe acute exacerbations of hepatitis; therefore, close follow-up is necessary after stopping therapy.
Use in pregnancy should be considered only if the potential benefit justifies the risk to the fetus.
Patients should avoid concurrent use of nephrotoxic drugs unless advised by a healthcare professional.
Adverse Reactions:
Entecavir is generally well tolerated. Commonly reported side effects include headache, fatigue, dizziness, nausea, and increased ALT levels. Rare but serious adverse events include lactic acidosis and hepatomegaly with steatosis, which require immediate medical attention.
Storage:
Store in a cool, dry place below 30°C, protected from moisture and direct sunlight. Keep out of reach of children.
Quality Assurance by Kureasia Pharma:
At Kureasia Pharma, we are committed to delivering advanced and reliable antiviral therapies that meet international standards of quality, efficacy, and safety. Our Entecavir Tablets undergo rigorous testing, ensuring consistent purity and therapeutic performance. Through continuous innovation and excellence in pharmaceutical manufacturing, Kureasia Pharma supports global healthcare initiatives in the fight against viral hepatitis